Cleared Traditional

TDX R OPIATES (K854421) - FDA 510(k) Clearance

Class II Chemistry device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K854421 · Abbott Laboratories · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 1985
Decision
21d
Days
Class 2
Risk

K854421 is an FDA 510(k) clearance for the TDX R OPIATES. Classified as Enzyme Immunoassay, Opiates (product code DJG), Class II - Special Controls.

Submitted by Abbott Laboratories (Abbott Park, US). The FDA issued a Cleared decision on November 25, 1985 after a review of 21 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.3650 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Abbott Laboratories devices

Submission Details

510(k) Number K854421 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 04, 1985
Decision Date November 25, 1985
Days to Decision 21 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
67d faster than avg
Panel avg: 88d · This submission: 21d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DJG Enzyme Immunoassay, Opiates
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3650
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - DJG Enzyme Immunoassay, Opiates

All 88
Devices cleared under the same product code (DJG) and FDA review panel - the closest regulatory comparables to K854421.
LABELING CHANGE COAT-A-COUNT MORPHINE IN URINE
K873757 · Diagnostic Products Corp. · Oct 1987
LABELING CHANGE COAT-A-COUNT SERUM MORPHINE
K873758 · Diagnostic Products Corp. · Oct 1987
ACA DU PONT URINE OPIATES (U OPI) SCREEN METHOD
K872391 · E.I. Dupont DE Nemours & Co., Inc. · Aug 1987
EMIT D.A.U. OPIATE ASSAY
K842677 · Syva Co. · Sep 1984
EMIT 700 OPIATE ASSAY
K843162 · Syva Co. · Sep 1984
MODIF. OF EMIT URINE OPIATE ASSAY
K833581 · Syva Co. · Jan 1984